Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EC 70124

Next Previous
Drug Profile

EC 70124

Alternative Names: EC-70124

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EntreChem
  • Developer OrphAI Therapeutics
  • Class Antineoplastics; Carbazoles; Indoles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; I-kappa B kinase inhibitors; Janus kinase 2 inhibitors; MTOR protein inhibitors; NF-kappa B kinase inhibitors; Proto-oncogene protein c-akt inhibitors; Ribosomal protein S6 kinase inhibitors; STAT3 transcription factor inhibitors; STAT5 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Solid tumours
  • No development reported Cancer; Prostate cancer

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Prostate-cancer in Spain (PO)
  • 28 Sep 2023 AI Therapeutics is now called OrphAI Therapeutics
  • 25 Nov 2022 Preclinical development for Prostate cancer is ongoing Spain (EntreChem pipeline, November 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top